Rapport Therapeutics Inc（RAPP）股票分析RAPPRapport Therapeutics Inc

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rapport Therapeutics Inc is currently not a strong buy due to its recent performance and financial losses. The stock is priced at $25.93 with a 5-day change of -5.95% and a 20-day change of -23.53%. Although analysts have set a price target as high as $79.03, the company reported a significant Q2 net loss of $56.6 million, which raises concerns about its financial health. The RSI is at 33.465, indicating the stock is oversold, but the overall trend remains negative. The main risk is the ongoing financial losses, with a net income loss of $56.6 million in Q2 2026, which could deter potential investors in the short term.